Abingdon Health Plc (LSE:ABDX) — Market Cap & Net Worth
Market Cap & Net Worth: Abingdon Health Plc (ABDX)
Abingdon Health Plc (LSE:ABDX) has a market capitalization of $259.67K (GBX2.13 Billion) as of May 2, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30747 globally and #991 in its home market, demonstrating a -10.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abingdon Health Plc's stock price GBX8.50 by its total outstanding shares 251077850 (251.08 Million). Analyse ABDX cash flow metrics to see how efficiently the company converts income to cash.
Abingdon Health Plc Market Cap History: 2020 to 2026
Abingdon Health Plc's market capitalization history from 2020 to 2026. Data shows change from $2.88 Million to $259.67K (-37.36% CAGR).
Index Memberships
Abingdon Health Plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$928.08 Million | 0.03% | #272 of 722 |
Weight: Abingdon Health Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Abingdon Health Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abingdon Health Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Abingdon Health Plc's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.88 Million | $5.24 Million | -$3.37 Million | 0.55x | N/A |
| 2021 | $1.01 Million | $11.62 Million | -$6.97 Million | 0.09x | N/A |
| 2022 | $198.57K | $2.83 Million | -$21.26 Million | 0.07x | N/A |
| 2023 | $336.04K | $4.04 Million | -$3.47 Million | 0.08x | N/A |
| 2024 | $236.75K | $6.13 Million | -$1.27 Million | 0.04x | N/A |
| 2025 | $195.51K | $8.43 Million | -$3.42 Million | 0.02x | N/A |
Competitor Companies of ABDX by Market Capitalization
Companies near Abingdon Health Plc in the global market cap rankings as of May 2, 2026.
Key companies related to Abingdon Health Plc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Abingdon Health Plc Historical Marketcap From 2020 to 2026
Between 2020 and today, Abingdon Health Plc's market cap moved from $2.88 Million to $ 259.67K, with a yearly change of -37.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX259.67K | +32.81% |
| 2025 | GBX195.51K | -17.42% |
| 2024 | GBX236.75K | -29.55% |
| 2023 | GBX336.04K | +69.23% |
| 2022 | GBX198.57K | -80.30% |
| 2021 | GBX1.01 Million | -64.98% |
| 2020 | GBX2.88 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Abingdon Health Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $259.67K USD |
| MoneyControl | $259.67K USD |
| MarketWatch | $259.67K USD |
| marketcap.company | $259.67K USD |
| Reuters | $259.67K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Abingdon Health Plc
Abingdon Health Plc develops, manufactures, and distributes diagnostic devices in the United Kingdom, Europe, the United States, Canada, and internationally. It operates through Contract Development, Contract Manufacturing, Product Sales, and Regulatory segments. The company provides a range of professional-use tests and self-tests to various industries, including healthcare, COVID-19, plant heal… Read more